SCHEMBL5225906

SCHEMBL5225906

COCCN(C)c1ccc(CC(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
NR1H4 Q96RI1 1/20 0.43
CA2 P00918 1/20 0.43
CAMK2A Q9UQM7 1/20 0.43
LTB4R Q15722 4/20 0.42
LTB4R2 Q9NPC1 4/20 0.42
NR3C1 P04150 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
AKR1B1 P15121 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PPARG P37231 1/20 0.41
NR1H2 P55055 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28344644 0.84 LTB4R (0.46) ALDH1A1LMNALTB4RLTB4R2HPGD
SCHEMBL17316330 0.82 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10KDM4EGAA
SCHEMBL18562081 0.80 BRAF (0.41) ALDH1A1HPGDHSD17B10TSHRHTT
SCHEMBL23291208 0.80 LTB4R (0.40) LTB4RLTB4R2PPARG
SCHEMBL9271571 0.80 NR1H4 (0.46) ALDH1A1LMNANR1H4CA2CAMK2A
SCHEMBL1756743 0.80 MEN1 (0.45) ALDH1A1CA2RXRARXRBHPGD
SCHEMBL23928220 0.78 ALDH1A1 (0.42) ALDH1A1LMNAKDM4E
SCHEMBL17316388 0.78 DGAT1 (0.47) LTB4RLTB4R2NR1H2NR1H3
SCHEMBL13498385 0.78 GRM1 (0.37) ALDH1A1HPGDTSHRTDP1
SCHEMBL17316664 0.78 ALDH1A1 (0.52) ALDH1A1LMNANR1H4CA2CAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414429-B Pyrazole compounds and their use as T-type calcium channel blockers 爱杜西亚药品有限公司 2020-01-03 CN disclosed
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-09-04 US disclosed
US-9932314-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-04-03 US disclosed
EP-3152199-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS Actelion Pharmaceuticals Ltd. (CH) 2017-04-12 EP disclosed
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS IDORSIA PHARMACEUTICALS LTD (CH) 2017-04-06 US disclosed
WO-2015186056-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS ACTELION PHARMACEUTICALS LTD (CH) 2015-12-10 WO disclosed
EP-1781649-A2 SUBSTITUTED HYDANTOINS F. Hoffmann-Roche AG (CH) 2007-05-09 EP disclosed
WO-2006018188-A2 SUBSTITUTED HYDANTOINS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers CACNA1E, CACNA1I, CACNA1G ALDH1A1 3435/4885LMNA 1368/4885NR1H4 3305/4885
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1I, CACNA1G ALDH1A1 3435/4885LMNA 1368/4885NR1H4 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.